

■日程表  
Day 1, July 27 (Thu)

		7	8	9	10	11	12	13	14	15	16	17	18	19	
神戸国際会議場	Room 1 (ポートピアホール)	南館 1F		開会式	SY1 免疫チェックポイント阻害薬の副作用とその対策 9:00-11:00			会長特別企画 がん診療一均てん化はどこまで進んだか?~ 12:30-14:30		JSMO15周年記念企画 がん薬物治療の変遷 14:40-16:40					
	Room 2 (コンベンションホール南)	2号館 1F			ISY1 Latest status of EGFR-TKIs in EGFR mutant NSCLCs 9:00-11:00	MeS-1 11:20-12:10 徹底討論、がん免疫治療、今何が課題か。		EL1 13:00-13:30 分子標的薬のバイオマーカー探索 検証のための臨床試験デザイン	EL2 13:30-14:00 胃がんに対する薬物療法	EL3 14:00-14:30 大腸癌に対する薬物療法の現状と展望	ISY2 14:30-16:30 Biomarker research and treatment strategy for metastatic colorectal cancer	ES-1 16:50-17:40 大腸癌治療の最新動向、免疫療法、分子標的薬、免疫チェックポイント阻害薬、それぞれの特徴			
	Room 3 (コンベンションホール北)	2号館 1F			WS1 緩和ケア病棟転院時の患者・家族の見捨てられ感について ~安心して転院できますか 9:20-11:00	MeS-2 11:20-12:10 大腸がん薬物療法の最新動向 ~各種ガイドラインを臨床にどう活かすか?~		WS2 13:00-14:40 がん治療中の患者のdecision makingのサポート~がん治療する?しない?~		SY2 14:50-16:30 症状スクリーニングと緩和治療 ~早期からの緩和ケアを目指して~					
	Room 4 (Hall A)	1号館 2F			SY3 我が国の大腸がん化学療法臨床試験と、その位置づけ 9:00-11:00	MeS-3 11:20-12:10 Metastatic Colorectal Cancer: From Disease Biology to Clinical Management		SY4 12:30-14:30 日本人ゲノム配列とがん ~精度の高い日本人ゲノム配列情報を活用したがんゲノム研究の最前線~		JS6 14:40-16:40 合同シンポジウム6 (日本癌学会 / 日本癌治療学会 / 日本対がん協会 / 日本臨床腫瘍学会) 学友会における「がん教育」~本邦活動の年における現状と課題~		ES-2 16:50-17:40 HER2増強進行再発がんに対するアヒズチン/タキセル療法 日本のがん安全性			
	Room 5 (Hall B)	1号館 2F			PD New developing treatment for advanced esophageal cancer 9:00-11:00	MeS-4 11:20-12:10 New Developments of Advanced Gastric Cancer Treatment		ISY3 12:30-14:40 Recent advances in the treatment of multiple myeloma		WS3 14:40-16:30 進行期メラノーマ治療の最前線		ES-3 16:50-17:40 頭頸部癌におけるがん免疫療法。その背景にあるものと臨床データ			
	Room 6 (2A会議室)	2号館 2F				MeS-5 11:20-12:10 Lenalidomide Based Treatment: New Treatment Concept of Transient Irreleigle Multiple Myeloma		JS1 12:40-14:40 合同シンポジウム1 (日本放射線腫瘍学会 / 日本臨床腫瘍学会) 新規抗癌剤と放射線治療		WS4 14:50-16:30 定位放射線照射 現状と適応拡大に向けて		ES-4 16:50-17:40 進行扁平上皮肺がんに対する治療戦略			
	Room 7 (2B会議室)	2号館 2F				MeS-6 11:20-12:10 腸・消化管神経内分泌腫瘍の最新の診断と治療 ~WHO2017 新分類を踏まえて~						ES-5 16:50-17:40 B型肝炎の再活性化のUpdate			
	Room 8 (3A会議室)	2号館 3F			SY5 がんプロ推進プランの到達点と今後の展望 9:00-11:00	MeS-7 11:20-12:10 EGFR遺伝子変異陽性肺がん ~最適な治療戦略を考える~		SY6 12:40-14:40 癌に対するエビゲノム創薬の現在と今後の展望		SY7 14:50-16:30 各種臓器がんの骨転移に対する最新治療戦略		ES-6 16:50-17:40 進行がんの治療と緩和ケア			
	Room 9 (3B会議室)	2号館 3F			O1-1 9:00-10:00 橋渡し研究1	O1-2 10:00-11:00 橋渡し研究2	MeS-8 11:20-12:10 悪性軟部腫瘍の治療とパソパニブの適正使用		O1-3 13:30-14:30 基礎医学	O1-4 14:30-15:30 臨床薬理	O1-5 15:30-16:30 分子標的治療	ES-7 16:50-17:40 次世代シークエンスを用いたドライバー変異陽性肺がんに対する新たな治療戦略			
神戸国際会議場 (KCC)	Room 10 (メインホール)	1F		EL4 9:00-9:30 我が国における造血器腫瘍に対する新規薬剤の最新情報	EL5 9:30-10:00 30分で身につく英語論文作成に必須のスキルとツール	EL6 10:00-10:30 地域医療とクリティカルパス	EL7 10:30-11:00 ゲノム医療	MeS-9 11:20-12:10 Strategic choices in the management of metastatic colorectal cancer	SL1 12:30-13:00 Histamine N-methyltransferase as a potential therapeutic target for the Her2+ breast cancer patients	EL8 13:00-13:30 泌尿器がんの薬物療法	EL9 13:30-14:00 診療ガイドラインとEBM ~診療ガイドラインの限界	EL10 14:00-14:30 がん患者とのコミュニケーション	WS5 14:30-16:30 アカデミア発がん薬開発の進展	ES-8 16:50-17:40 なぜ外来で化学療法できないの? ~あすから外来化学療法が実現できる4人のエピソードによる現状~	
	Room 11 (国際会議室)	3F		WS6 9:00-11:00 原発不明がん診断・治療の新たな方向性		MeS-10 11:20-12:10 発熱性好中球減少症から患者を守れ! ~四国がんセンター肺癌医療チームの挑戦~		ISY4 12:30-14:30 Guidelines of Molecular Targeted Therapies for Thyroid Cancer		ISY5 14:30-16:30 Immunotherapy for head and neck cancer: Future direction		ES-9 16:50-17:40 Non-Driver Mutation NSCLC 治療シークエンスの再考			
	Room 12 (レセプションホール)	3F		O1-6 9:00-10:00 脳神経	O1-7 10:00-11:00 頭頸部	MeS-11 11:20-12:10 Therapy of relapsed myeloma: an update		O1-8 13:30-14:30 乳がん1	O1-9 14:30-15:30 乳がん2	O1-10 15:30-16:30 乳がん3	ES-10 16:50-17:40 HER2陽性進行再発乳癌治療の現在と未来				
	Room 13 (501会議室)	5F		SY8 9:00-11:00 AYA世代がんの治療の現状と展望		MeS-12 11:20-12:10 Folfinrox in pancreatic cancer: Present and future		WS7 12:20-14:20 胆道癌の化学療法:今後の展望		ISY6 14:30-16:30 Chemotherapy for advanced pancreatic cancer in a new era		ES-11 16:50-17:40 がん医療のエッセンス: コミュニケーションスキルがアートか			
	Room 14 (502会議室)	5F		ガイドライン委員会企画 発熱性好中球減少症(FN) 診療ガイドライン改訂版の解説 9:00-10:30		MeS-13 11:20-12:10 Current standards and unsolved question in the treatment of sarcoma in advance phase		SY9 12:30-14:30 軟部肉腫の集学的治療:臨床の現場から	EL11 14:30-15:30 Sarcoma: Harnessing the Complexities of Cancer and Its Care	O1-11 15:30-16:30 骨軟部腫瘍	ES-12 16:50-17:40 プレジジョンメディスンにおける次世代シーケンサーの臨床応用				
	Room 15 (504+505会議室)	5F		O1-12 9:00-10:00 神経内分泌	O1-13 10:00-11:00 血液1(リンパ腫)	MeS-14 11:20-12:10 What is the current and future Treatment Strategy against EGFR positive lung cancer		O1-14 13:30-14:30 分子・遺伝子診断	O1-15 14:30-15:30 血液2(MDS・白血病)	O1-16 15:30-16:30 血液3(多発性骨髄腫・リンパ腫)	ES-13 16:50-17:40 全量検体のがんゲノムスクリーニングに基づく、がんPrecision Medicine 実現に向けた取り組み				
	PAP会場 (401+402会議室)	4F		PAP 9:30-10:00 オリエンテーション	PAP 10:00-11:00 「エビデンス」ってなんだろう	PAP 11:20-12:10 ランチョンセミナー: 日本のがん対策を知ろう		会長特別企画 (中継) 12:30-14:30		PAP 14:50-16:20 相互交流プログラム1 私たちの患者会活動 (岡山会場と中継)					
神戸国際会議場	ポスター会場 (展示室)	3号館 1F		8:00-9:00 ポスター貼付									8:00-18:00 P 18:00-19:00 19:00-19:30	ポスターセッション ポスター撤去	

**凡例**

- JS = Joint Symposium
- ISY = International Symposium
- SY = Symposium
- WS = Workshop
- PD = Panel Discussion
- EL = Educational Lecture
- SL = Special Lecture
- M&S = Medical Seminar
- ES = Evening Seminar
- O = Oral
- P = Poster

同時通訳 (英⇄日)  
English Session  
Sponsored by 高松宮妃癌研究基金

19:00~20:30  
会員懇親会  
会場: 神戸国際展示場 3号館  
ポスター会場内

**Time Table**  
**Day 1, July 27 (Thu)**

			7	8	9	10	11	12	13	14	15	16	17	18	19		
Kobe International Exhibition Hall	Kobe International Conference Center (ICCK)	Room 1 (Portopia Hall)	South Building 1F		Opening Remarks	SY1 Countermeasures against side effects by immune check point inhibitors			President's Special Program How far have we eliminated disparities in cancer care?		JSMO 15th Anniversary Session Progress of Drug Therapy for Cancer						
		Room 2 (Convention Hall South)	Hall No.2 1F			ISY1 Latest status of EGFR-TKIs in EGFR mutant NSCLCs		MeS-1 Discussion, what are emerging issues in IO treatment?		EL1 Biomarker-driven clinical trial designs for targeted therapies	EL2 Systemic chemotherapy for metastatic gastric cancer	EL3 Current status and future perspective of chemotherapy for colorectal cancer	ISY2 Biomarker research and treatment strategy for metastatic colorectal cancer	ES-1 Better management of the later line treatment for mCRC - Roles of physicians and medical staff-			
		Room 3 (Convention Hall North)	Hall No.2 1F			WS1 About a good coping method with feeling of abandonment in patients and their families at transfer to palliative care unit (PCU) ~Can you transfer to PCU with relieved and trust?		MeS-2 New era of oncological treatment for metastatic colorectal cancer ~How to Translate Various Guidelines into Clinical Practice-		WS2 Decision making support for patients who are treating advanced cancer ~Would you like to do further cancer treatment, or not?~		SY2 Comprehensive Symptom Screening and Early Palliative care ~From the Start of Cancer Treatment					
		Room 4 (Hall A)	Hall No.1 2F			SY3 Investigator initiated trials for colorectal cancer in Japan		MeS-3 Metastatic Colorectal Cancer: From Disease Biology to Clinical Management		SY4 Update on Japanese reference genome and cancer genome sequence		JS6 Joint Symposium 6 (JCA/JSCO/JCS/JSMO) "Cancer Education" -Current Status and Challenges in the Year of Full-scale Start at Schools		ES-2 Safety of AVASTIN + Paclitaxel therapy for HER2-negative metastatic breast cancer in Japan			
		Room 5 (Hall B)	Hall No.1 2F			PD New developing treatment for advanced esophageal cancer		MeS-4 New Developments of Advanced Gastric Cancer Treatment		ISY3 Recent advances in the treatment of multiple myeloma		WS3 Update on Therapeutic approaches for advanced melanoma		ES-3 Rationale and clinical data for Immunology of head and neck cancer			
		Room 6 (Conference Room 2A)	Hall No.2 2F					MeS-5 Lenalidomide Based Treatment: New Treatment Concept of Transplant Ineligible Multiple Myeloma		JS1 Joint Symposium 1 (JASTRO/JSMO) Combination of Radiotherapy and New Anticancer Agents		WS4 Stereotactic Irradiation: Present situation and future indications		ES-4 Treatment strategy for Advanced squamous cell carcinoma of the lung			
		Room 7 (Conference Room 2B)	Hall No.2 2F					MeS-6 Recent Updates On Diagnosis and Treatment of Pancreatic and Gastrointestinal Neuroendocrine Tumors ~WHO2017: A new classification-						ES-5 Update of reactivation of hepatitis B virus			
		Room 8 (Conference Room 3A)	Hall No.2 3F			SY5 Overview and Future Prospect of "Promotion Plan for the Platform of Human Resource Development for Cancer"		MeS-7 Optimal Treatment Strategies for EGFR mutation-positive NSCLC		SY6 Present and Future of epigenome drug discovery against cancers		SY7 Treatment of bone metastasis: updated strategy		ES-6 Palliative Care for Patients with Advance/Metastatic Cancer			
		Room 9 (Conference Room 3B)	Hall No.2 3F			O1-1 Translational Research 1	O1-2 Translational Research 2	MeS-8 Treatment modality of soft tissue sarcoma and appropriate treatment with Pazopanib		O1-3 Basic Research	O1-4 Clinical Pharmacology	O1-5 Molecular Targeted Therapy		ES-7 Therapeutic Strategy of Genomic Biomarker Testing using Next-generation Sequencing in Lung Cancer Patients with Driver Gene Mutation			
Room 10 (Main Hall)	1F			EL4 Up to date information of novel drugs in hematologic malignancies in Japan	EL5 Academic Writing 101	EL6 Cancer care and treatment in community and the critical path for cancer	EL7 Genomic medicine	MeS-9 Strategic choices in the management of metastatic colorectal cancer	SL1 Histamine Hmethyltransferase as a potential therapeutic marker for the HER2+ breast cancer patients	EL8 Systemic therapy for genitourinary cancers	EL9 Clinical Practice Guideline and EBM Clinical Practice Guideline's Limitations	EL10 Communicating with Cancer Patients	WS5 Role of academia in anticancer drug discovery and development	ES-8 Why can't you give outpatient chemotherapy? ~Tips by four experts for administering outpatient chemotherapy beginning tomorrow~			
Room 11 (International Conference Room)	3F			WS6 New directions in the diagnosis and treatment of carcinoma of unknown primary		MeS-10 Save a patient's life from febrile neutropenia - Medical Team Challenge in Shikoku Cancer Center		ISY4 Guidelines of Molecular Targeted Therapies for Thyroid Cancer		ISY5 Immunotherapy for head and neck cancer: Future direction		ES-9 Reconsideration of treatment sequence in NSCLC without driver mutation					
Room 12 (Reception Hall)	3F			O1-6 Brain Tumor	O1-7 Head and Neck Cancer	MeS-11 Therapy of relapsed myeloma: an update		O1-8 Breast Cancer 1	O1-9 Breast Cancer 2	O1-10 Breast Cancer 3		ES-10 HER2-positive metastatic breast cancer: current and future treatment					
Room 13 (501)	5F			SY8 Current status and perspective of treatment for adolescent and young adults with cancer		MeS-12 Folfinrox in pancreatic cancer: Present and future		WS7 Future prospects of chemotherapy for biliary tract cancer		ISY6 Chemotherapy for advanced pancreatic cancer in a new era		ES-11 Essence of Cancer medicine: Communication Skills? or Arts?					
Room 14 (502)	5F			A brief overview of a revised edition of the Japanese guideline for the management of febrile neutropenia		MeS-13 Current standards and unsolved question in the treatment of sarcoma in advance phase		SY9 Multidisciplinary approach to soft tissue sarcoma: Current management		EL11 Sarcoma: Harnessing the Complexities of Cancer and Its Care	O1-11 Bone and Soft Tissue Tumors	ES-12 Applications of NGS in Precision Cancer Management					
Room 15 (504+505)	5F			O1-12 Neuroendocrine Tumors	O1-13 Hematological Malignancies 1 (Lymphoma)	MeS-14 What is the current and future Treatment Strategy against EGFR positive lung cancer		O1-14 Molecular / Genetic Diagnosis	O1-15 Hematological Malignancies 2 (MDS / Leukemia)	O1-16 Hematological Malignancies 3 (Myeloma / Lymphoma)		ES-13 Challenge and Initiative toward Precision Medicine for Cancer Patients through the Nationwide Cancer Genome Screening Project					
Patient Advocate Program (401+402)	4F			PAP 9:30-10:00	PAP 10:00-11:00	PAP 11:20-12:10		President's Special Program (Relay)		PAP 14:50-16:20							
Poster Area	Hall No.3 1F		8:00-9:00	Poster Set-up					Poster Display				9:00-18:00	P 18:00-19:00	19:00-19:30		
															Welcome Party at Poster Area		
															Explanatory Notes		
															<ul style="list-style-type: none"> <li>JS =Joint Symposium</li> <li>ISY =International Symposium</li> <li>SY =Symposium</li> <li>WS =Workshop</li> <li>PD =Panel Discussion</li> <li>EL =Educational Lecture</li> <li>SL =Special Lecture</li> <li>MeS =Medical Seminar</li> <li>ES =Evening Seminar</li> <li>O =Oral</li> <li>P =Poster</li> <li> Simultaneous Interpretation (E&amp;J)</li> <li> English Session</li> <li> Sponsored by Princess Takamatsu Cancer Research Fund</li> </ul>		





■日程表  
Day 3, July 29 (Sat)

		7	8	9	10	11	12	13	14	15	16	17	18	19	
神戸国際 展示場	Room 1 (ポートピアホール)	南館 1F			ISY14 Cancer Immunotherapy -What's the next? EJ ESMO/JSMO 合同シンポジウム Optimal treatment for metastatic colorectal cancer (based on revised, latest ESMO, JSCCR treatment guideline)										
	Room 2 (コンベンションホール南)	2号館 1F		WS13 がん看護外来の活動とその成果	8:40-10:10	SY20 チームで取り組む分子標的薬の副作用マネジメント 患者へベネフィットをもたらす支持療法	10:20-12:20								
	Room 3 (コンベンションホール北)	2号館 1F		SY22 合併症を有する患者への横断的アプローチ	8:20-10:20	SY23 分子標的治療薬の臨床薬理学的研究	10:20-12:20								
	Room 4 (Hall A)	1号館 2F		SPS セミプレナリーセッション	8:20-10:20	SY25 クリニカルバイオバンクを活用した 早期臨床開発の可能性を探る	10:20-12:20								
	Room 5 (Hall B)	1号館 2F		O3-1 呼吸器4 (免疫療法)	8:20-9:20	O3-2 呼吸器5 (分子標的薬1)	9:20-10:20	O3-3 呼吸器6 (分子標的薬2)	10:20-11:20	O3-4 呼吸器7 (分子標的薬3)	11:20-12:20				
	Room 6 (2A会議室)	2号館 2F	MoS-11 7:20-8:10 非小細胞肺癌の二次治療に おける免疫チェックポイント 阻害剤の考え方	O3-7 食道がん	8:20-9:30	O3-8 胃がん1	9:30-10:20	O3-9 胃がん2	10:20-11:20	O3-10 胃がん3	11:20-12:20				
	Room 7 (2B会議室)	2号館 2F	MoS-12 7:20-8:10 Considerations for sequencing of therapy for metastatic castration resistant prostate cancer												
	Room 8 (3A会議室)	2号館 3F	MoS-13 7:20-8:10 去勢抵抗性前立腺癌の最新 潮流-病態と実診療から 治療戦略を考える-	JS4 合同シンポジウム4 (日本循環器学会 / 日本臨床腫瘍学会) Cardio-Oncology -循環器専門医と腫瘍内科医の連携-	8:20-10:20	SY27 臨床研究法下での臨床試験の行方	10:20-12:20								
	Room 9 (3B会議室)	2号館 3F	MoS-14 7:20-8:10 骨髄異形成症候群 (MDS)の診断	JS5 合同シンポジウム5 (日本製薬医学会 / 日本臨床腫瘍学会) 本邦における医療技術評価 (HTA)の最新動向	8:20-10:20	SY28 MDS診療の新たな展開	10:20-12:30								
神戸国際 会議場 (KCC)	Room 10 (メインホール)	1F		EL23 8:20-8:50 原発不明癌	EL24 8:50-9:20 がんサイバ シップ研究と 実践/ブリック ヘルスの視点 から	EL25 9:20-9:50 緩和とケア における EBM	EL26 9:50-10:20 がん化学療法 のB型肝炎ウィ ルス再活性化の リスクと その対策	EL27 10:20-10:30 がん連携 における 在宅支持 療法	EL28 10:30-11:20 がんの リハビリ テーション	EL29 11:20-11:50 がん患者の 家族への サポート	EL30 11:50-12:20 分子標的薬 の獲得耐性 と耐性克服 治療				
	Room 11 (国際会議室)	3F	MoS-15 7:20-8:10 R/R PTCLに おける新しい 治療選択肢	SL7 8:50-9:50 Future and Prospective Strategy for Follicular Lymphoma		ISY15 New therapeutic strategy for endocrine-refractory metastatic breast cancer	10:20-12:20								
	Room 12 (レセプションホール)	3F		WS15 9:20-10:40 Oligometastases		WS16 10:50-12:20 粒子線治療:正確なエビデンス作り を目指して									
	Room 13 (501会議室)	5F		O3-11 8:20-9:20 子宮・卵巣	O3-12 9:20-10:20 泌尿器がん	SY30 10:20-12:20 Treatment Strategy for Castration Resistant Prostate Cancer, 2017									
	Room 14 (502会議室)	5F		SY31 8:40-10:40 専門医のキャリアパス- 腫瘍内科とがん薬物療法専門医の未来を 考える		専門医部会 企画ケースカンファレンス	10:40-12:20								
	Room 15 (504+505会議室)	5F		SY32 8:20-10:20 ゲノム医療にかかわる人材育成	O3-13 10:20-11:20 曝露対策	O3-14 11:20-12:20 看護									
	Room 16 (503会議室)	5F				若手がん臨床研究者養成プログラム 「がん臨床研究塾」	10:00-12:30								
	PAP会場 (401+402会議室)	4F		PAP 9:30-10:20 がん患者と家族の こころのケア	PAP 10:30-11:20 がん暮らし	PAP 11:30-12:20 がんリハビリ テーション									
神戸国際 展示場	ポスター会場 (展示室)	3号館 1F		8:00-9:00 ポスター貼付											

**凡例**

- EJ =ESMO/JSMO Joint Symposium
- SPS =Semi-Plenary Session
- JS =Joint Symposium
- ISY =International Symposium
- SY =Symposium
- WS =Workshop
- EL =Educational Lecture
- SL =Special Lecture
- MoS =Morning Seminar
- MeS =Medical Seminar
- ES =Evening Seminar
- O =Oral
- P =Poster

T 同時通訳 (英⇄日)  
E English Session  
S Sponsored by 高松宮妃癌研究基金

**Time Table**  
**Day 3, July 29 (Sat)**

			7	8	9	10	11	12	13	14	15	16	17	18	19				
Kobe International Exhibition Hall	Kobe International Conference Center (ICCK)	Room 1 (Portopia Hall)	South Building 1F			ISY14 Cancer Immunotherapy -What's the next?	EJ ESMO/JSMO Joint Symposium Optimal treatment for metastatic colorectal cancer (based on revised, latest ESMO, JSCCR treatment guideline)					SL5 Targeting immune regulation for cancer immunotherapy	EL21 Current medication for lung cancer	EL22 Updates in clinical development of immune checkpoint inhibitors					
		Room 2 (Convention Hall South)	Hall No.2 1F		WS13 The outcomes from nursing activities at the oncogenic outpatient unit		SY20 Adverse Event Management of Molecular Targeted Drugs by Interdisciplinary Medical Team Supportive Care which benefits Patients			MeS-29 The treatment strategy of NSCLC using anti-PD-1 antibody-How do we interpret the result of clinical trials to the clinical practice-?		SY21 Evidence & Practice: Outpatient Cancer Rehabilitation							
		Room 3 (Convention Hall North)	Hall No.2 1F			SY22 Multidisciplinary approach to cancer patients having complications		SY23 Clinical Pharmacology Studies of Tyrosine kinase inhibitors		MeS-30 Personalized treatment of non-small cell lung cancer, from cytotoxic agents, molecular targets to immunotherapy		SY24 Current status and problems of obtaining pharmaceutical approval and insurance coverage for multigene assay as a medical device							
		Room 4 (Hall A)	Hall No.1 2F		SPS Semi-Plenary Session		SY25 Discussing potential role of the clinical biobanks in early-phase clinical development			MeS-31 Recent Advances in Biology and Treatment of Myeloma Bone Disease		JS3 Joint Symposium 3 (JPOS/JSMO) Communication in cancer care and psychooncological support -The trajectory of the past decade and the near future-							
		Room 5 (Hall B)	Hall No.1 2F		O3-1 Lung Cancer 4 (Immunotherapy)	O3-2 Lung Cancer 5 (Molecular-targeted drug 1)	O3-3 Lung Cancer 6 (Molecular-targeted drug 2)	O3-4 Lung Cancer 7 (Molecular-targeted drug 3)		MeS-32 Reflecting on last 15 years - EGFR-TKI -		O3-5 Colorectal Cancer 3	O3-6 Colorectal Cancer 4						
		Room 6 (Conference Room 2A)	Hall No.2 2F	MoS-11 Concept of ICI treatment for NSCLC in the second line setting	O3-7 Esophageal Cancer	O3-8 Gastric Cancer 1	O3-9 Gastric Cancer 2	O3-10 Gastric Cancer 3		MeS-33 The role of second generation ALK-TKI in ALK+ NSCLC		SY26 Future prospects of treatments for advanced hepatocellular carcinoma							
		Room 7 (Conference Room 2B)	Hall No.2 2F	MoS-12 Considerations for sequencing of therapy for metastatic castration resistant prostate cancer						MeS-34 New therapeutic strategies of neuroendocrine tumor									
		Room 8 (Conference Room 3A)	Hall No.2 3F	MoS-13 The current trend of CRPC -the treatment strategy from biology and real world practice-	JS4 Joint Symposium 4 (JCS/JSMO) Cardio-Oncology - Future-oriented Cooperation between Cardiologist and Oncologist		SY27 Whereabouts of the Clinical Trial under the Clinical Research Act			MeS-35 Key drug of later line chemotherapy in metastatic colorectal cancer -Let's learn Regorafenib-		SL6 Molecular Genetics of Endometrial Carcinoma: The Past, Present and Future	WS14 Present and Future of ovarian cancer treatment						
		Room 9 (Conference Room 3B)	Hall No.2 3F	MoS-14 Diagnosis of myelodysplastic syndromes (MDS)	JS5 Joint Symposium 5 (JAPhMed/JSMO) Recent trends of Health Technology Assessment (HTA) in Japan		SY28 New developments for pathogenesis and treatment of MDS			MeS-36 The medical oncologist's past and future role in cooperative and adjuvant chemotherapy for gastric cancer									
Kobe International Conference Center (ICCK)	Kobe International Conference Center (ICCK)	Room 10 (Main Hall)	1F	EL23 Cancer survivorship research and care practices from a public health perspective	EL24 Evidence-based medicine in palliative care	EL25 Management of hepatitis B virus reactivation in cancer patients treated with systemic chemotherapy	EL26 Community-based supportive care for cancer patients at home	EL27 Rehabilitation for Cancer Patients	EL28 Support for families/caregivers of cancer patients	EL29 Acquired resistance to targeted drugs and novel therapy to overcome the resistance	EL30	MeS-37 Mechanisms of Endocrine Resistance in ER+ Breast Cancer	EL31 Upfront in drug therapy of advanced melanoma	EL32 Targeted therapy for cerebral metastasis	EL33 Understanding key issues of clinical trial articles in 30 minutes	EL34 Clinical pharmacology of older adult patients with cancer			
		Room 11 (International Conference Room)	3F	MoS-15 New treatment options of R/R PTCL	SL7 Future and Prospective Strategy for Follicular Lymphoma	ISY15 New therapeutic strategy for endocrine-refractory metastatic breast cancer			MeS-38 Follicular lymphoma - current standards of the ESMO guidelines		ISY16 Present and future status of hereditary cancer prophylactics								
		Room 12 (Reception Hall)	3F		WS15 Oligometastases	WS16 Particle Therapy: The creation of concrete evidence			MeS-39 Optimizing integration of genomics in cancer treatment approaches		SY29 Clinical pharmacology and therapeutics for cancer chemotherapy								
		Room 13 (501)	5F	O3-11 Gynecological Cancer	O3-12 Urologic Cancer	SY30 Treatment Strategy for Castration Resistant Prostate Cancer, 2017			MeS-40 Topics of palliative medicine / supportive care in medical oncology										
		Room 14 (502)	5F		SY31 Future perspectives of medical oncology and board-certified medical oncologists				MeS-41 Clinical questions and future perspective of immuno-oncology										
		Room 15 (504+505)	5F	SY32 Development of a genetic diagnostic education resource	O3-13 Anti Exposure Management	O3-14 Oncology Nursing			MeS-42 Precision medicine in Lung Cancer: New possibility of Crizotinib		O3-15 Team Medical Care 1	O3-16 Team Medical Care 2							
		Room 16 (503)	5F																
		Patient Advocate Program (401+402)	4F		PAP	PAP	PAP			PAP		PAP							
Kobe International Conference Center (ICCK)	Kobe International Conference Center (ICCK)	Poster Area	Hall No.3 1F	8:00-9:00	Poster Display										9:00-14:00	P 14:00-14:50	14:50-15:20		

**Explanatory Notes**

- EJ =ESMO/JSMO Joint Symposium
- SPS =Semi-Plenary Session
- JS =Joint Symposium
- ISY =International Symposium
- SY =Symposium
- WS =Workshop
- EL =Educational Lecture
- SL =Special Lecture
- MoS =Morning Seminar
- MeS =Medical Seminar
- ES =Evening Seminar
- O =Oral
- P =Poster

I Simultaneous Interpretation (E&J)  
 E English Session  
 S Sponsored by Princess Takamatsu Cancer Research Fund

Closing Remarks